HomeMarketBlueprint Med...

Blueprint Medicines Corporation (NASDAQ:BPMC) stock is trading 19.22 percent above its 52-week low

Wells Fargo raised the price target for the Blueprint Medicines Corporation (NASDAQ:BPMC) stock from “an Underweight” to “an Equal weight”. The rating was released on January 03, 2023, according to finviz. The stock was initiated by Berenberg, who disclosed in a research note on September 14, 2022, to Buy and set the price objective to $90. In their research brief published July 08, 2022, Oppenheimer analysts initiated the Blueprint Medicines Corporation stock to Outperform with a price target of $80.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Blueprint Medicines Corporation (NASDAQ:BPMC) raised 0.22% to close Friday’s market session at $45.09, higher as compared to yesterday’s close. The stock price fluctuated between $44.00 and $45.63 throughout the trading session with the volume trading being 998681 shares, which represented a significant variation when compared to the three months average volume of 567.94K shares. The firm’s stock price fluctuated 7.36% within the last five trades and 2.41% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -37.88% in the last 6 months and -3.51% was subtracted to its value over the previous 3 months. BPMC stock is trading at a margin of 3.56%, -0.38% and -15.13% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


As of the close of trading, BPMC deals in the Healthcare domain. The stock is trading -43.21 percent below its 52-week high and 19.22 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -41.71. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Blueprint Medicines Corporation’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $2.78 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 13.62 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 5.24, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Albers Jeffrey W., the Director at Blueprint Medicines Corporation (BPMC) has sold 9,793 shares of firm on Mar 06 at a price of $45.67 against the total amount of $0.45 million. In another inside trade, Haviland Kate, CHIEF EXECUTIVE OFFICER of Blueprint Medicines Corporation (NASDAQ:BPMC) sold 6,640 shares of the firm on Mar 06 for a total worth of $0.3 million at a price of $45.69. An inside trade which took place on Mar 06, EVP AND CHIEF LEGAL OFFICER of Blueprint Medicines Corporation McCain Tracey L sold 3,322 shares of firm against total price of $0.15 million at the cost of $45.68 per share.



Please enter your comment!
Please enter your name here

Recent Post